<p>An interim analysis of long-term treatment results for 202 patients with acute lymphoblastic leukemia (ALL), aged 15–60 years, received therapy according protocol ALL-2009 was shown. The basic principle of ALL-2009 was non-aggressive, but continued cytostatic exposure, as well as the reproducibility in a regional hematology centers. Long-term treatment results of ALL-2009 are 2 times higher than the previously obtained in adult ALL patients within the Russian clinical multicenter studies of adult ALL. The 5‑year overall survival of patients younger than 30 years was 73.6 %, relapse-free survival (RFS) – 71.5 %, compared with 52.7 % and 61.8 % in patients aged 30 years and older, respectively. In patients with B-precursor ALL with normal ...
International audienceAllogeneic hematopoietic cell transplantation is widely used to treat adults w...
The MRC UKALL XA trial for patients aged 15 years and over with acute lymphoblastic leukaemia was de...
For decades, Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) has been considered the AL...
Objectives As new, effective therapies emerge for acute lymphoblastic leukaemia (ALL), the results o...
Objectives: As new, effective therapies emerge for acute lymphoblastic leukaemia (ALL), the results ...
Acute lymphoblastic leukemia (ALL), a common child malignancy, also constitutes a minor fraction of ...
Treatment results and clinical characteristics in adult acute lymphoblastic leukaemia (ALL) were eva...
Acute lymphoblastic leukemia (ALL) has poor prognosis in older/elderly adults and in high-risk/relap...
Adult Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph1-positive ALL) represents ab...
International audienceThe outcome of adult patients with Philadelphia chromosome-negative acute lymp...
Thirty-nine consecutive patients with acute lymphoblastic leukemia were treated with an intensive ch...
The international acute lymphoblastic leukemia (ALL) study was designed to prospectively define the ...
The case histories of 293 adolescent and adult patients with acute lymphoblastic leukemia (ALL) firs...
Background and Objectives: In adult acute lymphoblastic leukaemia (ALL), unlike in childhood ALL, th...
International audienceAllogeneic hematopoietic cell transplantation is widely used to treat adults w...
The MRC UKALL XA trial for patients aged 15 years and over with acute lymphoblastic leukaemia was de...
For decades, Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) has been considered the AL...
Objectives As new, effective therapies emerge for acute lymphoblastic leukaemia (ALL), the results o...
Objectives: As new, effective therapies emerge for acute lymphoblastic leukaemia (ALL), the results ...
Acute lymphoblastic leukemia (ALL), a common child malignancy, also constitutes a minor fraction of ...
Treatment results and clinical characteristics in adult acute lymphoblastic leukaemia (ALL) were eva...
Acute lymphoblastic leukemia (ALL) has poor prognosis in older/elderly adults and in high-risk/relap...
Adult Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph1-positive ALL) represents ab...
International audienceThe outcome of adult patients with Philadelphia chromosome-negative acute lymp...
Thirty-nine consecutive patients with acute lymphoblastic leukemia were treated with an intensive ch...
The international acute lymphoblastic leukemia (ALL) study was designed to prospectively define the ...
The case histories of 293 adolescent and adult patients with acute lymphoblastic leukemia (ALL) firs...
Background and Objectives: In adult acute lymphoblastic leukaemia (ALL), unlike in childhood ALL, th...
International audienceAllogeneic hematopoietic cell transplantation is widely used to treat adults w...
The MRC UKALL XA trial for patients aged 15 years and over with acute lymphoblastic leukaemia was de...
For decades, Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) has been considered the AL...